Posted by Michael Wonder on 14 Feb 2025
ViiV Healthcare and the pan-Canadian Pharmaceutical Alliance successfully finalise negotiations for Apretude for HIV-1 pre-exposure prophylaxis
13 February 2025 - ViiV Healthcare is pleased to announce it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for Apretude (cabotegravir tablets and extended release injectable suspension) for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in at-risk individuals who are HIV-1 negative.
ViiV Healthcare is committed to ensuring timely public access for Apretude to help reduce the risk of sexually acquired HIV-1 infection and make progress towards global targets of ending HIV by 2030, which Canada endorsed.
